tiprankstipranks
Corcept Therapeutics (CH:HTD)
NASDAQ:HTD
Switzerland Market
HTD
Corcept Therapeutics
RESEARCH TOOLSreports

Corcept Therapeutics (HTD) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

HTD Analyst Ratings

Strong Buy
4Ratings
Strong Buy
4 Buy
0 Hold
0 Sell
Based on 4 analysts giving stock ratings to
Corcept
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

HTD Stock 12 Month Forecast

Average Price Target

$79.13
Based on 4 Wall Street analysts offering 12 month price targets for Corcept Therapeutics in the last 3 months. The average price target is $79.13 with a high forecast of $109.57 and a low forecast of $58.44. The average price target represents a ― change from the last price of ―.
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
Highest Price Target$109.57Average Price Target$79.13Lowest Price Target$58.44
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on CH:HTD
Swayampakula Ramakanth
H.C. Wainwright
H.C. Wainwright
CHF77.1
Buy
―
Reiterated
06/02/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Bristol-Myers Squibb (NYSE: BMY), Corcept Therapeutics (NASDAQ: CORT) and Taysha Gene Therapies (NASDAQ: TSHA)
Piper Sandler Analyst forecast on CH:HTD
David Amsellem
Piper Sandler
Piper Sandler
CHF71.42
Buy
―
Reiterated
06/01/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Canaccord Genuity Analyst forecast on CH:HTD
Edward Nash
Canaccord Genuity
Canaccord Genuity
CHF89.28→CHF109.57
Buy
―
Reiterated
05/28/26
Corcept Therapeutics price target raised to $135 from $110 at CanaccordCorcept Therapeutics price target raised to $135 from $110 at Canaccord
UBS Analyst forecast on CH:HTD
Ashwani Verma
UBS
UBS
CHF58.44
Buy
―
Upgraded
05/13/26
Corcept Therapeutics upgraded to Buy from Neutral at UBSCorcept Therapeutics upgraded to Buy from Neutral at UBS
Wolfe Research Analyst forecast on CH:HTD
Kalpit Patel
Wolfe Research
Wolfe Research
―
Hold
―
Upgraded
03/26/26
Corcept Therapeutics upgraded to Peer Perform from Underperform at Wolfe ResearchCorcept Therapeutics upgraded to Peer Perform from Underperform at Wolfe Research
Truist Financial Analyst forecast on CH:HTD
Joon Lee
Truist Financial
Truist Financial
―
Buy
―
Reiterated
03/02/26
Wall Street Analysts Are Bullish on Top NA Picks
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on CH:HTD
Swayampakula Ramakanth
H.C. Wainwright
H.C. Wainwright
CHF77.1
Buy
―
Reiterated
06/02/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Bristol-Myers Squibb (NYSE: BMY), Corcept Therapeutics (NASDAQ: CORT) and Taysha Gene Therapies (NASDAQ: TSHA)
Piper Sandler Analyst forecast on CH:HTD
David Amsellem
Piper Sandler
Piper Sandler
CHF71.42
Buy
―
Reiterated
06/01/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Canaccord Genuity Analyst forecast on CH:HTD
Edward Nash
Canaccord Genuity
Canaccord Genuity
CHF89.28→CHF109.57
Buy
―
Reiterated
05/28/26
Corcept Therapeutics price target raised to $135 from $110 at CanaccordCorcept Therapeutics price target raised to $135 from $110 at Canaccord
UBS Analyst forecast on CH:HTD
Ashwani Verma
UBS
UBS
CHF58.44
Buy
―
Upgraded
05/13/26
Corcept Therapeutics upgraded to Buy from Neutral at UBSCorcept Therapeutics upgraded to Buy from Neutral at UBS
Wolfe Research Analyst forecast on CH:HTD
Kalpit Patel
Wolfe Research
Wolfe Research
―
Hold
―
Upgraded
03/26/26
Corcept Therapeutics upgraded to Peer Perform from Underperform at Wolfe ResearchCorcept Therapeutics upgraded to Peer Perform from Underperform at Wolfe Research
Truist Financial Analyst forecast on CH:HTD
Joon Lee
Truist Financial
Truist Financial
―
Buy
―
Reiterated
03/02/26
Wall Street Analysts Are Bullish on Top NA Picks
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Corcept Therapeutics

3 Months
Swayampakula RamakanthH.C. Wainwright
Success Rate
16/20 ratings generated profit
80%
Average Return
+18.40%
Copying Swayampakula Ramakanth's trades and holding each position for 3 Months would result in 80.00% of your transactions generating a profit, with an average return of +18.40% per trade.
1 Year
Swayampakula RamakanthH.C. Wainwright
Success Rate
17/20 ratings generated profit
85%
Average Return
+62.70%
Copying Swayampakula Ramakanth's trades and holding each position for 1 Year would result in 85.00% of your transactions generating a profit, with an average return of +62.70% per trade.
2 Years
David AmsellemPiper Sandler
Success Rate
26/26 ratings generated profit
100%
Average Return
+87.79%
Copying David Amsellem's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +87.79% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

HTD Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
12
16
14
11
5
Buy
3
5
2
5
5
Hold
1
1
1
1
0
Sell
1
0
0
0
0
Strong Sell
0
0
0
0
0
total
17
22
17
17
10
In the current month, HTD has received 10 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. HTD average Analyst price target in the past 3 months is 79.13.
Each month's total comprises the sum of three months' worth of ratings.

HTD Financial Forecast

HTD Earnings Forecast

Next quarter’s earnings estimate for HTD is <$0.01 with a range of -$0.07 to $0.05. The previous quarter’s EPS was -$0.23. HTD beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year HTD has Performed in-line its overall industry.
Next quarter’s earnings estimate for HTD is <$0.01 with a range of -$0.07 to $0.05. The previous quarter’s EPS was -$0.23. HTD beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year HTD has Performed in-line its overall industry.

HTD Sales Forecast

Next quarter’s sales forecast for HTD is $170.96M with a range of $163.84M to $175.55M. The previous quarter’s sales results were $128.66M. HTD beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year HTD has Performed in-line its overall industry.
Next quarter’s sales forecast for HTD is $170.96M with a range of $163.84M to $175.55M. The previous quarter’s sales results were $128.66M. HTD beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year HTD has Performed in-line its overall industry.

HTD Stock Forecast FAQ

What is CH:HTD’s average 12-month price target, according to analysts?
Based on analyst ratings, Corcept Therapeutics’s 12-month average price target is 79.13.
    What is CH:HTD’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for CH:HTD, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is Corcept Therapeutics a Buy, Sell or Hold?
        Corcept Therapeutics has a consensus rating of Strong Buy, which is based on 4 buy ratings, 0 hold ratings and 0 sell ratings.
          What is Corcept Therapeutics’s share price target?
          The average share price target for Corcept Therapeutics is 79.13. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is $109.57 ,and the lowest forecast is $58.44. The average share price target represents N/A Increase from the current price of N/A.
            What do analysts say about Corcept Therapeutics?
            Corcept Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.
              How can I buy shares of Corcept Therapeutics?
              To buy shares of CH:HTD, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.